Pau D Arco Tabebuia.

Lapacho inner bark is the traditional part of Tabebuia used for pau d'arco preparations. The two supply the same naphthoquinone profile, so their amounts add rather than complement.

Lapachol is the marker naphthoquinone of pau d'arco bark and the constituent most preparations are standardised against. Combining them raises total naphthoquinone exposure from one source chemistry.

Beta-lapachone is derived from lapachol and occurs in the same bark. Both are ortho-naphthoquinones handled by the same reductive metabolism.

Lapachol is a naphthoquinone structurally close to vitamin K and acts as an antagonist at vitamin K dependent carboxylation, which is why lowered prothrombin was recorded in early human work. Vitamin K status is the direct counterweight.

Lapachol interferes with vitamin K dependent clotting factor carboxylation while nattokinase acts on fibrin. Stacking them pushes normal clotting in the same direction from two separate points.

Ginkgolides antagonise platelet activating factor while pau d'arco naphthoquinones oppose vitamin K dependent carboxylation. The two act on different steps of the same clotting sequence.

EPA shifts eicosanoid balance away from thromboxane A2 and lowers platelet aggregation. Combined with the vitamin K antagonism of lapachol, both arms of normal clotting are affected at once.

Beta-lapachone is a substrate for NAD(P)H quinone oxidoreductase 1 and drives a futile redox cycle that consumes NADH and NADPH. NAD precursor status therefore shapes how much of that cycling a cell can sustain.

Lapachol and related bark naphthoquinones share the 1,4-naphthoquinone ring that defines the vitamin K family, and substituted naphthoquinones can interfere with the vitamin K epoxide reductase cycle that regenerates the active cofactor. That makes co-use with a menaquinone worth flagging as a possible interaction on the same enzyme cycle rather than a complementary pairing. The concern comes from the shared chemistry, not from a trial of the two together.

Because the plant's principal constituents are naphthoquinones, anything depending on vitamin K dependent gamma-carboxylation sits on a pathway these compounds can plausibly touch. Anyone tracking their vitamin K dependent clotting parameters should regard the combination as a monitoring point. Mechanistic reasoning, no combination measurement.

Garlic organosulfur compounds reduce platelet aggregation in laboratory and human marker studies, and naphthoquinone-containing bark preparations have been described as affecting clotting parameters. Stacking two agents that both nudge platelet function is a caution rather than a benefit. Neither the size nor the direction of the combined effect has been measured.

Salicin from willow bark is metabolised to salicylate, which inhibits platelet cyclooxygenase. Adding a second bark preparation with reported effects on clotting parameters compounds that. Flagged as an interaction to watch, not a pairing to build a formula around.

Bromelain has documented fibrinolytic and antiaggregatory activity in laboratory work. Combined with a naphthoquinone bark that has itself been linked to clotting parameter changes, the stack pushes the same direction twice. No study measured the pair.

Bark decoctions carry tannins, and tannins form insoluble complexes with non-heme iron in the gut lumen, which is a well described absorption competition for tea and other tannin-rich infusions. Taking a bark tea with an iron dose therefore predictably lowers how much of that iron dose is absorbed. Separating the two by a couple of hours is the ordinary formulation answer.

Ferrous sulfate delivers non-heme iron, the exact species tannins bind. A tannin-containing bark preparation taken at the same time reduces the fraction available for uptake at the duodenal transporter. Established gut chemistry rather than a trial finding.

Ascorbate reduces ferric to ferrous iron and competes with polyphenols for it, which is why vitamin C is used to blunt tannin inhibition of iron uptake. Separately, ascorbate participates in the redox cycling of quinones, so it can change the oxidation state of the bark's naphthoquinones in the same solution. Two distinct effects, both from established chemistry.

Naphthoquinones are conjugated and reduced in the liver, and silymarin modulates several of the same conjugating and transport steps. Traditional herbal practice pairs a strong botanical with a liver-supportive one, and this pairing is that practice rather than a measured interaction. Direction and magnitude are unknown.

Quercetin and the bark's naphthoquinones both undergo glucuronidation and sulfation and both can enter one-electron redox cycles. Co-dosing loads the same conjugation capacity. This is a plausible interaction on shared metabolism, not a demonstrated additive effect.

Michael addition of glutathione to a quinone ring is the textbook route by which cells dispose of electrophilic quinones, and repeated quinone exposure draws on that glutathione pool. This is why quinone-rich botanicals are discussed alongside thiol status. Established biochemistry, with no human study of this specific pairing.